This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novo Nordisk (NVO) to Begin Study on Oral Semaglutide in Obesity
by Zacks Equity Research
Novo Nordisk (NVO) to start a phase IIIa study testing oral semaglutide 50 mg in people with obesity or those who are overweight with comorbidities. The study is expected to begin in second-half 2021.
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Honeywell International, Novo Nordisk and Starbucks
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Honeywell International, Novo Nordisk and Starbucks
Top Stock Reports for Microsoft, JPMorgan & Honeywell
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), JPMorgan (JPM), and Honeywell (HON).
AstraZeneca (AZN) Farxiga COVID-19 Study Fails to Meet Goal
by Zacks Equity Research
AstraZeneca's (AZN) phase III study on Farxiga in hospitalized COVID-19 patients with pre-existing health conditions fails to show statistical significance for the primary endpoint
Top Analyst Reports for Facebook, Adobe & Novo Nordisk
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Adobe (ADBE), and Novo Nordisk (NVO).
Why Novo Nordisk (NVO) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes? Let's find out.
Gilead (GILD) Expands NASH Collaboration With Novo Nordisk
by Zacks Equity Research
Gilead (GILD) expands collaboration with Novo Nordisk for developing NASH treatments.
4 Stocks in Focus as Diabetes Sector Grows Amid Pandemic
by Debanjana Dey
Here are a few diabetes-centric MedTech stocks, ABT, NVO, MDT, PODD and TNDM, which investors can focus on to reap profits in the new normal.
The Zacks Analyst Blog Highlights: Novo Nordisk, NextEra Energy, 3M Co, General Motors and U.S. Bancorp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novo Nordisk, NextEra Energy, 3M Co, General Motors and U.S. Bancorp
Top Analyst Reports for Novo Nordisk, NextEra & 3M Company
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk (NVO), NextEra Energy (NEE), and 3M Company (MMM).
Intercept's (ICPT) Q4 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Intercept (ICPT) posts a wider loss and misses on sales in the fourth quarter of 2020.
Top Research Reports for Berkshire Hathaway, Walmart & Home Depot
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway (BRK.B), Walmart (WMT) and Home Depot (HD).
Q4 Earnings Scorecard and Analyst Reports for Sony, Mondelez & Twilio
by Sheraz Mian
We have provided a real-time update on the Q4 earnings season, in addition to featuring new research reports on 16 major stocks in today's Research Daily.
Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beats both earnings and sales estimates for the fourth quarter of 2020.
Vertex's (VRTX) IND for Type I Diabetes Drug Gets FDA Clearance
by Zacks Equity Research
Vertex (VRTX) gets FDA clearance for the investigational new drug application of VX-880, for the potential treatment of type I diabetes.
The Zacks Analyst Blog Highlights: Facebook, Novo Nordisk, SAP, Royal Dutch Shell and American Express
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Novo Nordisk, SAP, Royal Dutch Shell and American Express
Top Research Reports for Facebook, Novo Nordisk & SAP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Novo Nordisk (NVO), and SAP SE (SAP).
Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?
by Zacks Equity Research
Gilead (GILD) gains more than 19% in the past month and is poised to post a robust performance in the year ahead on strong HIV franchise.
Top Analyst Reports for Amazon, Thermo Fisher & Eli Lilly
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Thermo Fisher Scientific (TMO), and Eli Lilly (LLY).
Gilead (GILD) Ups Revenue Guidance on Increased Veklury Demand
by Zacks Equity Research
Gilead (GILD) lifts guidance for 2020, driven by increased Veklury (remdesivir) sales for COVID-19 as the pandemic worsens.
AstraZeneca (AZN) Farxiga Gets Priority Tag for Kidney Disease
by Zacks Equity Research
If approved for CKD, AstraZeneca's (AZN) Farxiga will be the first SGLT2 inhibitor approved to treat patients with CKD, with and without type II diabetes.
Pfizer's (PFE) BLA for Somatrogon Gets FDA's Acceptance
by Zacks Equity Research
Pfizer's (PFE) BLA for growth hormone deficiency (GHD) gets accepted by the FDA for standard review. FDA's decision expected in October 2021.
Novo Nordisk (NVO) Files for Ozempic's Label Expansion in EU
by Zacks Equity Research
Novo Nordisk (NVO) files for a label expansion of Ozempic in the EU to include a new dose of 2.0 mg.
Top Analyst Reports for Alphabet, Comcast & Accenture
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Comcast (CMCSA) and Accenture (ACN).
Novo Nordisk (NVO) Files for Semaglutide Label Expansion in EU
by Zacks Equity Research
Novo Nordisk (NVO) files application in Europe for the label expansion of subcutaneous Ozempic (semaglutide) 2.4 mg.